【摘要】 为了观察国产重组酵母乙型肝炎 (乙肝 )疫苗的免疫原性和预防效果 ,在广西壮族自治区隆安县农村地区不筛检孕妇乙肝表面抗原 (HBsAg) ,对新生儿普种国产重组酵母乙肝疫苗 ,并于免疫后 1、2、4年进行血清学监测。结果显示 :5 μg× 3剂国产重组酵母乙肝疫苗初免后 ,1～ 4岁儿童的HBsAg阳性率已由免疫前的 11 9%降至 2 0 % ,保护率为 83 2 % ;免疫后抗 HBs阳转率峰值为 84 4%～ 88 2 %。 3～ 4年下降为 71 3%、6 6 0 % ,但保护效果不变。可见 ,国产重组酵母乙肝疫苗具有较好免疫原性 ,完全可以取代血源性乙肝疫苗纳入计划免疫对新生儿普种更多还原

【Abstract】 For evaluating the immunogenicity and preventive efficacy of the domestic recombinant yeast-derived hepatitis B vaccine in newborns,we have brought the recombinant yeast-derived hepatitis B vaccine into EPI,and the newborns in the county were universally immunized without screening their mothers’ HBsAgThe serologic surveys were conducted at 1,2 and 4 years after vaccinationThe results showed that after 5μg×3 doses of recombinant yeast-derived hepatitis B vaccination,the HBsAg positive rate decreased from 119% in 1987 before the immunization program to 20% in 2000,the protective rate was 832%The anti-HBs positive seroconversion peak rate observed was 844%-882%,it decreased to 713% and 660% 3 and 4 years later,but the protective rate remained unchangedThis demonstrated that the recombinant yeast-derived hepatitis B vaccine has good immunogenicity and high protection against hepatitis B infection,it may be brought into EPI to replace the plasma-derived hepatitis B vaccine for universal vaccination of newborns更多还原